PARP1 and cancer: The development of PARP inhibitors (PARPi), such as Olaparib1 and Talazoparib2, to treat BRCA-deficient breast cancer3,4 opened up a new therapeutic strategy for cancer subtype-specific chemotherapy, synthetic lethality5–7.